M344 (Synonyms: D237, Histone Deacetylase Inhibitor III, MS 344) |
Katalog-Nr.GC16456
One-Click Copy Product Info
|
HDAC-Inhibitor
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 251456-60-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
M344 is a histone deacetylase (HDAC) inhibitor with an IC50 value of 100nM[1]. M344 exhibits potential for the treatment of Alzheimer's disease[2]. M344 effectively suppresses the growth and viability of various cancer cell types through multiple mechanisms[3-4].
In vitro, the addition of M344 (2.5–4μM) to HEK293 cells at 24 hours post-transfection during rAAV8 production significantly increased the genomic titer of recombinant adeno-associated virus[5]. Treatment of neuroblastoma cell lines SH-SY5Y, SK-N-BE(2), and KP-N-NS with M344 (1μM) for 12 hours markedly suppressed the mRNA and protein expression levels of c-Jun and Fra-1, while also reducing their phosphorylation activity[6].
In vivo, M344 (3–10mg/kg) was administered via intraperitoneal injection five days a week for 3-month-old Alzheimer's disease model mice for 4 months, which significantly improved their spatial memory and cognitive function[7].
References:
[1] Zhu M, Han Y, Gu T, et al. Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway. Cell Rep. 2024 Apr 23;43(4):114065.
[2] Jeong H, Shin S, Lee JS, et al. Pan-HDAC Inhibitors Promote Tau Aggregation by Increasing the Level of Acetylated Tau. Int J Mol Sci. 2019 Sep 1;20(17):4283.
[3] Yeung A, Bhargava RK, Ahn R, et al. HDAC inhibitor M344 suppresses MCF-7 breast cancer cell proliferation. Biomed Pharmacother. 2012 Apr;66(3):232-6.
[4] Knoche SM, Brumfield GL, Goetz BT, et al. The histone deacetylase inhibitor M344 as a multifaceted therapy for pancreatic cancer. PLoS One. 2022 Sep 20;17(9):e0273518.
[5] Scarrott JM, Johari YB, Pohle TH, et al. Increased recombinant adeno-associated virus production by HEK293 cells using small molecule chemical additives. Biotechnol J. 2023 Mar;18(3):e2200450.
[6] He W, Wu Y, Tang X, et al. HDAC inhibitors suppress c-Jun/Fra-1-mediated proliferation through transcriptionally downregulating MKK7 and Raf1 in neuroblastoma cells. Oncotarget. 2016 Feb 9;7(6):6727-47.
[7] Volmar CH, Salah-Uddin H, Janczura KJ, et al. M344 promotes nonamyloidogenic amyloid precursor protein processing while normalizing Alzheimer's disease genes and improving memory. Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):E9135-E9144.
| Cell experiment [1]: | |
Cell lines | SH-SY5Y, SK-N-BE(2), and KP-N-NS cells (human neuroblastoma cell lines) |
Preparation Method | Cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS). Cells were treated with M344 at a concentration of 1μM for 12 hours |
Reaction Conditions | 1μM; 12h |
Applications | M344 significantly suppressed the mRNA and protein expression levels of both c-Jun and Fra-1, inhibition of cell growth. M344 treatment caused MKK7 downregulation at both the protein and mRNA levels. |
| Animal experiment [2]: | |
Animal models | Triple transgenic Alzheimer's disease (3xTg-AD) mice (APPsw/PS1M146v/TauP301L) |
Preparation Method | Mice were intraperitoneally administered M344 at doses of 3mg/kg or 10mg/kg, 5 days per week for approximately 4 months, starting at 3 months of age (presymptomatic stage). Behavioral tests were conducted following the treatment period. |
Dosage form | 3 or 10mg/kg; i.p.; 5 days per week for approximately 4 months |
Applications | Chronic M344 treatment significantly prevented cognitive decline. Treated mice showed improved performance in Y-maze spontaneous alternation, novel object recognition and Barnes maze spatial memory tests compared to vehicle controls. M344 treatment also significantly decreased hippocampal Aβ1-42 levels and tau phosphorylation at Ser396, while increasing ADAM10 gene expression in the hippocampus. |
References: | |
| Cas No. | 251456-60-7 | SDF | |
| Überlieferungen | D237, Histone Deacetylase Inhibitor III, MS 344 | ||
| Chemical Name | 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide | ||
| Canonical SMILES | CN(C)C1=CC=C(C=C1)C(=O)NCCCCCCC(=O)NO | ||
| Formula | C16H25N3O3 | M.Wt | 307.39 |
| Löslichkeit | ≥ 14.75 mg/mL in DMSO, ≥ 12.88 mg/mL in EtOH with ultrasonic | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.2532 mL | 16.266 mL | 32.532 mL |
| 5 mM | 650.6 μL | 3.2532 mL | 6.5064 mL |
| 10 mM | 325.3 μL | 1.6266 mL | 3.2532 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)